Sign in Subscribe
Diseases

Semaglutide Demonstrates Vascular Benefits in Patients with Peripheral Artery Disease and Type 2 Diabetes

Strategic Insights

— 1 min read

Patients with peripheral artery disease (PAD) and type 2 diabetes who received semaglutide experienced significant improvement in symptoms, quality of life, and disease progression, according to new analysis presented at the American Diabetes Association's 85th Scientific Sessions. The study found that semaglutide reduced the risk of disease progression by 54% and improved walking capacity in patients with PAD and diabetes.

Key Takeaways:

  • Semaglutide reduced the risk of disease progression in patients with PAD and type 2 diabetes by 54%.
  • The study found significant improvement in symptoms, quality of life, and disease progression in patients with PAD and diabetes who received semaglutide.
  • The median age of participants was 68 years, and 195 (25%) participants were female and 597 (75%) were male.
  • Semaglutide significantly improved walking outcomes in people with PAD and diabetes, with an estimated median ratio to baseline in maximum walking distance of 1.21 at week 52.
  • The benefits of semaglutide were observed independent of baseline levels of A1C, duration of diabetes, or intensity of diabetes treatment.
  • The results were seen across all BMI categories and regardless of treatment with SGLT2 inhibitors.
  • The study authors indicate that further research is warranted to understand whether these benefits extend to individuals with PAD who do not have diabetes.
  • The study's findings suggest that semaglutide can be recognized as a vascular protective medication with benefits that extend beyond lowering weight or A1C.

Statistics:

  • 792 patients aged 18 years and older with type 2 diabetes and PAD participated in the STRIDE trial.
  • 396 patients received semaglutide, and 396 received placebo.
  • The median age of participants was 68 years.
  • 205 (25%) participants were female and 597 (75%) were male.
  • Semaglutide reduced the risk of disease progression by 54%.
  • The estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group.

Sources:

  • American Diabetes Association. (2025, June 21).
  • Diabetes Care. (2025, June 21).
  • American Diabetes Association. (2025). Annual Meeting Abstracts.

Read more